â– LECTURE OVERVIEW: Cori Disease (Glycogen Storage Disease Type III) is an autosomal recessive carbohydrate metabolism disorder characterized by the incomplete degradation of cellular glycogen.
â– PATHWAY ANALYSIS:
1. Debrancher Defect: Caused by a deficiency of the bifunctional Glycogen Debranching Enzyme (containing alpha-1,4 to alpha-1,4 glucan transferase and amylo-1,6-glucosidase activities).
2. Structural Structural Limits: Glycogen Phosphorylase can cleave alpha-1,4 glycosidic linkages until it reachers a limit dextrin (typically 4 glucose residues remaining on a branch).
3. Limit Dextrin Accumulation: Without debranching activity, glycogen degradation halts, leading to the accumulation of abnormal, highly branched glycogen molecules (limit dextrins) in the hepatic cytoplasm and skeletal muscle tissue.
4. Glucagon Response: Hypoglycemia is milder than in Von Gierke's (Type I) because gluconeogenesis remains 100% active and functional, allowing the liver to synthesize glucose de novo from lactate and amino acids.
â– BIOCHEMICAL MECHANISMS:
At the molecular level, enzyme kinetics govern reaction rates. Competitive inhibitors raise apparent Michaelis constants without changing maximum speed, whereas noncompetitive inhibitors decrease maximum speed directly.
â– SUBCLINICAL PHENOTYPE DYNAMICS:
Early physiological shifts typically occur without overt symptom presentation, necessitating highly sensitive laboratory screening to detect disease onset.
[HY-BOARD-1210]
🌟 Dynamic Clinical Key:
Cori disease presents with hepatomegaly, growth retardation, muscle weakness, and mild fasting hypoglycemia. It is differentiated from Von Gierke disease by the key presence of elevated creatine kinase (from muscle involvement), normal levels of lactic acid, and the histopathologic demonstration of limit dextrin aggregates. Focus on rate-limiting regulatory steps for pharmacological design. Monitor high-sensitivity panels regularly in at-risk cohorts to enable timely preventative actions.